Your browser is no longer supported. Please, upgrade your browser.
Settings
SLDB Solid Biosciences Inc. daily Stock Chart
SLDB [NASD]
Solid Biosciences Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own23.50% Shs Outstand32.11M Perf Week-1.14%
Market Cap279.68M Forward P/E- EPS next Y-2.31 Insider Trans- Shs Float23.02M Perf Month101.15%
Income-88.50M PEG- EPS next Q-0.69 Inst Own59.40% Short Float15.81% Perf Quarter57.79%
Sales- P/S- EPS this Y-84.30% Inst Trans-0.96% Short Ratio7.07 Perf Half Y-11.30%
Book/sh2.20 P/B3.96 EPS next Y22.70% ROA-75.70% Target Price8.93 Perf Year-77.36%
Cash/sh2.10 P/C4.15 EPS next 5Y- ROE-87.10% 52W Range4.32 - 54.54 Perf YTD-67.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.03% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low101.62% ATR0.83
Employees111 Current Ratio5.70 Sales Q/Q- Oper. Margin- RSI (14)67.26 Volatility10.22% 14.31%
OptionableYes Debt/Eq0.01 EPS Q/Q-50.10% Profit Margin- Rel Volume0.81 Prev Close9.03
ShortableYes LT Debt/Eq0.01 EarningsAug 09 Payout- Avg Volume514.36K Price8.71
Recom3.20 SMA2030.36% SMA5052.60% SMA200-37.46% Volume418,439 Change-3.54%
Aug-19-19Upgrade SVB Leerink Mkt Perform → Outperform $8 → $15
Aug-16-19Upgrade Chardan Capital Markets Neutral → Buy $7.50 → $10
May-14-19Downgrade Goldman Neutral → Sell $5 → $4
May-14-19Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19Upgrade Citigroup Sell → Neutral $8
Feb-08-19Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18Initiated Citigroup Sell
Sep-06-18Initiated Credit Suisse Neutral $38
Aug-20-19 12:20PM  Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 03:17PM  Solid Biosciences Stock Surge Ignites Options Activity Schaeffer's Investment Research +5.56%
08:58AM  Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-16-19 12:15PM  Here's Why Solid Biosciences Is Soaring Today Motley Fool +43.25%
Aug-15-19 02:41PM  Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings Bloomberg
Aug-14-19 07:25AM  Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire +23.79%
Aug-08-19 10:33AM  Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval Zacks +7.50%
Jul-26-19 07:25AM  Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors GlobeNewswire +34.41%
Jul-01-19 09:35AM  Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues Zacks -9.04%
09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
Jun-28-19 06:51PM  Heres What Hedge Funds Think About Solid Biosciences Inc. (SLDB) Insider Monkey +13.86%
04:28PM  Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying Investor's Business Daily
Jun-12-19 04:04PM  Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.25%
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
May-16-19 03:00PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) GlobeNewswire
10:00AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) ACCESSWIRE
May-14-19 04:27PM  This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note Investor's Business Daily -28.59%
01:56PM  Solid Bios Plunge Sends a Warning on Gene Therapies Bloomberg
12:26PM  Here's Why Solid Biosciences Fell as Much as 40.9% Today Motley Fool
11:51AM  Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial Benzinga
07:42AM  The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 04:10PM  Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-03-19 10:13AM  Heres What Hedge Funds Think About About Solid Biosciences Inc. (SLDB) Insider Monkey
Apr-17-19 11:10AM  Wave Life Sciences Plunges After DMD Study Data Readout Zacks
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-15-19 04:01PM  Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
Mar-28-19 10:20AM  Sarepta plans second Duchenne drug application this year American City Business Journals
Mar-13-19 07:30AM  Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +9.60%
Feb-20-19 03:52PM  Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc. PR Newswire +6.34%
Feb-15-19 08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-07-19 08:37PM  What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool -67.82%
04:11PM  Why This Biotech Stock Cratered 68% On Its Gene Therapy Study Investor's Business Daily
01:47PM  A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy Barrons.com
11:22AM  SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC Business Wire
11:05AM  Here's Why Solid Biosciences Plunged Today Motley Fool
10:45AM  Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals
09:42AM  Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg
09:25AM  Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug MarketWatch
06:45AM  Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy GlobeNewswire
Jan-02-19 08:00AM  Solid Biosciences to Present at the J.P. Morgan Healthcare Conference GlobeNewswire +7.91%
Nov-21-18 07:45AM  Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-13-18 07:00AM  Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update GlobeNewswire +10.48%
Nov-09-18 07:30AM  Solid Biosciences to Present at the Credit Suisse Healthcare Conference GlobeNewswire -6.39%
Oct-25-18 07:30AM  How This Underfollowed $6 Biotech Could Be Worth $10 ACCESSWIRE
Oct-05-18 04:05PM  Solid Biosciences to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Oct-01-18 08:00AM  Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-13-18 07:30AM  Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors GlobeNewswire -5.33%
Sep-06-18 02:47PM  Credit Suisse Joins Consensus To Prescribe Sarepta Benzinga -9.82%
Aug-30-18 02:00PM  CRISPR without consequences? Startup's drug shows promise in animal study American City Business Journals +5.06%
12:47PM  Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication MarketWatch
Aug-10-18 07:30AM  Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-01-18 10:03AM  Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate Benzinga
Jul-26-18 10:30AM  Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst Benzinga
Jul-05-18 03:19PM  A Look At IPOs So Far In 2018 Benzinga
Jul-03-18 09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool +7.87%
Jun-26-18 07:30AM  Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors GlobeNewswire -11.40%
Jun-25-18 08:53AM  Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress Benzinga
08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-23-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-22-18 08:41AM  DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus Zacks
Jun-20-18 01:47PM  This Biotech Is Cratering On Sarepta's Success But Could Be 'Superior' Investor's Business Daily -17.05%
08:32AM  Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Foundation Medicine and Solid Biosciences ACCESSWIRE
Jun-19-18 04:31PM  Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today Motley Fool +46.36%
04:25PM  Why Sarepta Therapeutics Stock Is Blasting Higher Today Motley Fool
04:21PM  Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug Zacks
01:29PM  Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy TheStreet.com
Jun-18-18 09:11AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +10.87%
08:29AM  UPDATE: Solid Biosciences stock surges on news FDA has removed clinical hold on SGT-001 DMD treatment MarketWatch
07:00AM  Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001 GlobeNewswire
Jun-12-18 04:29PM  This Biotech Investors Picks Returned 31% in Q1; Here Are Its New Bets Insider Monkey
May-29-18 01:38PM  Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the May 29th Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB) GlobeNewswire +7.49%
11:05AM  SLDB DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018 ACCESSWIRE
09:44AM  DEADLINE TODAY: Kaskela Law Alerts Solid Biosciences, Inc. Investors of Important Deadline Business Wire
May-27-18 10:50PM  SOLID BIOSCIENCES 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB Business Wire
May-26-18 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline SLDB GlobeNewswire
May-25-18 10:50PM  SOLID BIOSCIENCES 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Solid Biosciences Inc. Business Wire
04:42PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline SLDB GlobeNewswire
03:56PM  SOLID BIOSCIENCES LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm PR Newswire
03:11PM  DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action on Behalf of Solid Biosciences Inc. Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (SLDB) ACCESSWIRE
02:14PM  Solid Biosciences Inc. Reminder: Pawar Law Reminds of Important May 29, 2018 Lead Plaintiff Deadline in Class Action- SLDB ACCESSWIRE
10:45AM  FINAL DEADLINE NOTICE: Shareholder Class Action Lawsuit Against Solid Biosciences, Inc. Business Wire
May-24-18 07:35PM  SLDB $100,000 Threshold: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Solid Biosciences Inc. Investors GlobeNewswire
04:55PM  Bragar Eagel & Squire, P.C. Remind Investors That a Class Action Lawsuit Has Been Filed Against Solid Biosciences, Inc. (SLDB) and Encourages Investors to Contact the Firm Before May 29th ACCESSWIRE
03:00PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - SLDB ACCESSWIRE
10:38AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Solid Biosciences Inc. (SLDB) & Lead Plaintiff Deadline - May 28, 2018 ACCESSWIRE
08:30AM  Kessler Topaz Meltzer & Check LLP: Final Reminder for Solid BioSciences, Inc. Investors - SLDB ACCESSWIRE
May-23-18 06:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline - SLDB ACCESSWIRE
03:20PM  SLDB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018 ACCESSWIRE
11:30AM  IMPORTANT SHAREHOLDER DEADLINE ALERT: Solid Biosciences, Inc. - SLDB ACCESSWIRE
May-22-18 07:55PM  The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Solid Biosciences Inc. (SLDB) Business Wire
04:49PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm GlobeNewswire
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.